Advanced IP Workshop—Recent Developments in U.S. Life Sciences Patent Law

Finnegan’s Shanghai Office cordially invites you to attend the Advanced Intellectual Property Seminar Program series. This program features Finnegan attorneys Tom Irving, Paul Browning, and Yieyie Yang discussing Recent Developments in United States (U.S.) Life Sciences Patent Law. 

Tom Irving, with more than 40 years of experience in the field of intellectual property law, will discuss legal developments in the area of life science patent prosecution, due diligence, and inter partes reviews (IPRs). In particular, Tom will discuss strategies for securing U.S. patents with valid, enforceable claims designed to withstand challenges in both the courts and in USPTO post-grant proceedings. He will also address analyzing patent claims in a due diligence from the viewpoints of both the Target and Suitor and potential solutions to any issues found during that analysis. Finally, he will share ideas about what a patent owner should do if drawn into an inter partes review (IPR) proceeding.

Paul Browning, Ph.D., focuses on patent litigation and appeals, primarily in the chemical and pharmaceutical areas, and has led teams as first chair at trial, at Markman proceedings, and on appeal. He will discuss recent developments in U.S. patent law in the life science area and the impact of those changes on litigation practice. Among other things, he will discuss changes to U.S. venue law that affect where patent suits may be litigated in the United States, as well as recent judicial decisions that impact patent validity challenges in U.S. courts. Finally, he will provide guidance for Chinese companies that are contemplating or expecting litigation in U.S. courts.

Yieyie Yang, Ph.D., has experience in Abbreviated New Drug Application (ANDA) litigation, and prosecution, due diligence, IPR, and litigation of biological product patents. She will discuss the recent case law development regarding biosimilars litigation under the Biologics Price Competition and Innovation Act (BPCIA), including the timing of filing a declaratory judgment action, the exchange of information, asserting patents in the exchanged patent list, and the 180-day notice. She will also discuss the written description requirement for antibody patents from the perspectives of prosecution, IPR, and litigation.

Moderator:
Ningling Wang

Speakers:
Tom Irving
Paul Browning, Ph.D.
Yieyie Yang, Ph.D.

Agenda:
13:00 - 13:30   Registration
13:30 - 13:40   Welcome Remarks
13:40 - 14:50   Patent Prosecution, Due Diligence, and IPRs
14:50 - 15:10   Coffee Break
15:10 - 16:20   Patent Litigation
16:20 - 17:00   Patent Prosecution and IPRs related with Large Molecules
17:00 - 17:30   Questions and Answers

Date: 
Thursday, 29 March 2018

Venue:
The Ritz-Carlton Shanghai Pudong
Amber Room, 3rd Floor
Shanghai IFC, 8 Century Avenue, 
Lujiazui, Pudong New Area
Shanghai 200120

Register:
RSVP by 23 March 2018 to ipeventshanghai@finnegan.com.
Space is limited—by invitation only.